Announcements Trials
Browse Landscape

Phase

Phase 2 21Phase 1/2 13Phase 1 13Phase 3 3Phase 2/3 3Phase NA 1

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 2Myeloid 1Classical hematology 1

Conditions

Leukemia 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 1Lymphoma 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia, Eosinophilic, Acute 1Leukemia, Basophilic, Acute 1Congenital Abnormalities 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 11Cytarabine 8Methotrexate 6Etoposide 6Dexamethasone 6Vincristine 5Radiotherapy 5Doxorubicin 5Daunorubicin 5pegaspargase 4Trimethoprim, Sulfamethoxazole Drug Combination 4Mercaptopurine 4Idarubicin 4gamma-Globulins 3fludarabine phosphate 3Whole-Body Irradiation 3Prednisone 3N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3Methylprednisolone 3Gemtuzumab 3Filgrastim 3Clofarabine 3Ciprofloxacin 3Busulfan 3etoposide phosphate 2blinatumomab 2Thioguanine 2Melphalan 2Karyotyping 2Injections, Spinal 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × Leukemia × Clofarabine × Clear all
NCT03117751 2025-12-05

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

St. Jude Children's Research Hospital

Phase 2/3 Active not recruiting
790 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01228331 2024-12-11

Clofarabine or High-Dose Cytarabine and Pegaspargase in Children with ALL

Universitätsklinikum Hamburg-Eppendorf

Phase 2/3 Completed
745 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00454480 2013-08-26

Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

National Cancer Institute (NCI)

Phase 2/3 Completed
2,000 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Eosinophilic, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡